# LEVANTIS-0087A (GAGome test in adults without symptoms)

Source: https://onco.cc/trials/lev87a/  
OnCo record `lev87a` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Swedish study checking Elypta's sugar-molecule blood and urine test for many cancers on stored samples from people without symptoms.

## Summary

LEVANTIS-0087A (NCT05235009) is an observational study sponsored by Elypta. It is a retrospective case-control validation of free GAGome-based multi-cancer early detection tests in adults without symptoms and without recent cancer.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 9,170 participants, a start on 1 February 2022 and primary completion expected in December 2025.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Also known as: LEV87A
- Registry id: NCT05235009
- Phase: observational
- Setting: Adults without symptoms of cancer in a Swedish population cohort, using stored samples in a case-control validation of free GAGome tests
- Sponsor: Elypta
- Enrolled: 9170

## Sources

- ClinicalTrials.gov NCT05235009: https://clinicaltrials.gov/study/NCT05235009

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Elypta GAGome multi-cancer test](https://onco.cc/drugs/gagome-mced-test/)
- companies: [Elypta](https://onco.cc/companies/elypta/)

---
JSON: https://onco.cc/api/v1/entities/lev87a.json